Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: pedersen tr. Am J Transplant. 2005 Dec;5(12):2929-36. doi: 10.1111/j.1600-6143.2005.01105.x. Am J Transplant. 2005. PMID: 16303007 Clinical Trial.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Sabatine MS, et al. Among authors: pedersen tr. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15. Lancet Diabetes Endocrinol. 2017. PMID: 28927706 Clinical Trial.
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.
Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Deedwania PC, et al. Among authors: pedersen tr. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30. Int J Cardiol. 2016. PMID: 27513651 Clinical Trial.
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Nicholls SJ, et al. Among authors: pedersen tr. Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Clin Cardiol. 2018. PMID: 30125052 Free PMC article. Review.
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.
Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Giugliano RP, et al. Among authors: pedersen tr. Clin Cardiol. 2017 Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16. Clin Cardiol. 2017. PMID: 28207168 Free PMC article. Clinical Trial.
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: pedersen tr. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):315-20. doi: 10.1097/HJR.0b013e32832130f5. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19322096 Clinical Trial.
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: pedersen tr. Transplantation. 2005 Jan 27;79(2):205-12. doi: 10.1097/01.tp.0000147338.34323.12. Transplantation. 2005. PMID: 15665769 Clinical Trial.
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: pedersen tr. Kidney Int. 2004 Oct;66(4):1549-55. doi: 10.1111/j.1523-1755.2004.00919.x. Kidney Int. 2004. PMID: 15458450 Clinical Trial.
206 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page